Company profile
NOVOCURE LTD
NASDAQ:NVCRMedical/Dental Instruments
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PEMBROLIZUMAB | phase4 | — | 302 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04892472 | phase2 | terminated | 2021-07-12 | 2025-01-10 | NovoCure GmbH | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer |
| NCT06390059 | phase2 | completed | 2023-08-21 | 2025-11-18 | NovoCure Ltd. | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT06556563 | phase3 | recruiting | 2025-02-03 | 2029-04-01 | NovoCure GmbH | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma |
| NCT00916409 | phase3 | completed | 2009-06-01 | 2016-12-01 | NovoCure Ltd. | Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) |
| NCT02973789 | phase3 | completed | 2016-12-01 | 2024-09-24 | NovoCure GmbH | Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) |
FDA applications (0)
No records yet.